Results for: Diagnostics

The World Health Organization (WHO) has approved the first mpox in vitro diagnostic (IVD) under its Emergency Use Listing (EUL) procedure, a critical step in expanding global access to accurate and timely mpox testing. The Alinity m MPXV assay, produced by Abbott Molecular Inc., is a real-time PCR test that detects monkeypox virus DNA, aiding in the rapid confirmation of suspected cases. This move is particularly significant in countries experiencing mpox outbreaks, where quick and reliable testing is crucial for effective containment.

The global celiac disease diagnostics market is projected to reach US$ 626.2 million in 2024 and is expected to grow at a CAGR of 8.5% during the forecast period (2024 to 2034). Advancements in diagnostic technology, such as improved lateral flow assays and ELISA assays, are driving the market’s expansion. Increased public awareness, home-test kits, and new product launches are also contributing to the growth.

Artificial intelligence (AI) holds immense promise for revolutionizing healthcare, enabling improved diagnostics, personalized patient support, accelerated drug discovery, and increased efficiency. However, despite years of research, its integration into mainstream healthcare has been slow. This article explores the reasons behind this slow adoption, including data fragmentation, privacy concerns, regulatory challenges, and misaligned incentives. By addressing these obstacles, governments, regulators, and healthcare providers can unlock the full potential of AI to transform medical practices, improve outcomes, and save lives.

Different versions of RNA encoded by single genes may play a role in Alzheimer’s disease, according to a new study published in the journal ‘Science Advances’. The researchers analyzed brain tissue from deceased organ donors and found 700 RNA isoforms that had never been described before. Notably, the genes behind these isoforms were equally active in both groups of people with and without Alzheimer’s. However, the levels of nearly 100 of these isoforms differed in the brains of people with and without Alzheimer’s.

GE Healthcare (GEHC) reported mixed first-quarter results on Tuesday, with revenue and earnings slightly missing estimates. The company’s total revenue declined by 1% year over year to $4.65 billion, while adjusted earnings per share came in at $0.90, missing the consensus by 1 cent. Despite the disappointing results, GE Healthcare maintained its full-year guidance and expressed optimism about the business’s growth prospects. The market reacted negatively to the earnings, sending the stock down by nearly 14% in Tuesday’s trading session. However, analysts believe that the sell-off is an overreaction and that GEHC remains an attractive investment opportunity due to its strong market position and growth potential in areas such as Alzheimer’s disease diagnostics.

Danaher Corporation, a leading life sciences company, reported strong financial results for the first quarter of 2024, surpassing analyst estimates and indicating a recovery in the biotech industry. Revenue reached $5.8 billion, a 4% organic decline year-over-year but above expectations of $5.62 billion. Adjusted earnings per share (EPS) came in at $1.92, a 6.3% annual decrease but ahead of consensus estimates of $1.71 per share. Key operating segments all delivered better-than-expected results, including biotechnology, life sciences, and diagnostics.

The global biomarkers market is experiencing significant growth due to the increasing demand for companion diagnostics in the detection and treatment of various fatal diseases. This market is witnessing substantial research investments in the areas of Prostate and Lung cancer, Infectious disease diagnosis, Neurological diseases, and Cardiac problems. Product innovations and biomarker advancements are crucial in early detection, enabling the identification of the physiological state of cells and the activation of active genes.